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Background: In recent decades, Echovirus 30 (E30) and Japanese encephalitis virus (JEV) have been reported to be
the common causative agents of acute meningitis among patients in South East Asia. An E30 outbreak in Vietnam
in 2001–2002 gained our interest because the initial clinical diagnosis of infected patients was due to JEV infection.
There are few clinical insights regarding E30 cases, and there are no reports comparing E30 and JEV acute
meningitis/encephalitis cases based on clinical symptoms and case histories. We therefore aimed to identify reliable
clinical methods to differentiate E30 and JEV acute meningitis/encephalitis.
Methods: A retrospective, cross-sectional study was conducted to compare E30 and JEV acute meningitis/
encephalitis cases. We collected and analyzed the clinical records of 43 E30 confirmed cases (E30 group) and 60 JEV
confirmed cases (JEV group). Clinical data were compared between the E30 and the JEV groups. Differences of
clinical parameters were analyzed by certain statistical tests.
Results: Fever, headache, and vomiting were the most common symptoms in both the E30 and the JEV groups.
Combined symptoms of headache and vomiting and the triad of symptoms of fever, headache, and vomiting were
observed in more patients in the E30 group (E30 vs. JEV: 19% vs. 0%, p < 0.001; 74% vs. 27%, p < 0.001, respectively).
On the other hand, strong neurological symptoms such as seizure (5% vs. 73%, p < 0.001) and altered
consciousness (12% vs. 97%, p < 0.001) were manifested primarily in the JEV group. CSF leukocytosis was observed
predominantly in the E30 group (80 vs. 18 cells/μL, p = 0.003), whereas decreasing CSF sugar level was observed
predominantly in the JEV group (58.7 vs. 46.9 mg/dL, p < 0.001).
Conclusion: Fever, headache, vomiting, absence of neurological symptoms (seizure, altered consciousness), and
presence of CSF leukocytosis are important parameters to consider in differentiating E30 from JEV cases during
early infection. Then, proper measures can be adopted immediately to prevent the spread of the disease in the
affected areas.
Keywords: Echovirus 30, Japanese encephalitis virus, Acute meningitis/encephalitis* Correspondence: moritak@nagasaki-u.ac.jp
1Department of Virology, Institute of Tropical Medicine, Nagasaki University,
1-12-4, Sakamoto, 852-8523 Nagasaki, Japan
Full list of author information is available at the end of the article
© 2013 Takamatsu et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Takamatsu et al. Virology Journal 2013, 10:280 Page 2 of 9
http://www.virologyj.com/content/10/1/280Background
E30 is a positive-strand RNA virus that belongs to the
family Picornaviridae, genus Enterovirus [1]. It is transmit-
ted to humans by the oral-fecal route [2]. E30 is respon-
sible for many sporadic outbreaks of aseptic meningitis in
many countries because of its easier transmission [1-9].
Japanese encephalitis virus (JEV) is a mosquito-borne
virus that belongs to family Flaviviridae, genus Flavivirus
[10]. It can cause meningitis or encephalitis in humans. JEV
causes approximately 30,000-50,000 meningitis/encephalitis
cases annually in Asia, and it is one of the leading causes of
the meningitis/encephalitis cases worldwide [10,11]. In
recent decades, many E30 outbreaks have occurred in JEV-
endemic Asian countries around Vietnam [3,5,12-14].
According to several case reports on meningitis in these
countries, an epidemic season of E30 overlapped with that
of JEV [5,12,15,16]. Hence, certainty on clinical diagnosis
cannot be guaranteed, especially during the early course
of illness.
The general symptoms of Enterovirus meningitis are
headache, nausea, and vomiting. Common cold symp-
toms are also observed [1,5]. In some instances, severe
illness characterized by paralysis and encephalitis leads
to death [9,13]. These symptoms varying from mild to
severe manifestations are quite similar to those due to
JEV infection [11,17,18]. Thus, a correct identification of
the causative agent is difficult to determine based on the
clinical symptoms.
Several reports showed that JEV is one of the leading
causes of acute meningitis/encephalitis in Vietnam
[15,16,18]. However, the number of JEV-confirmed
cases was not high enough, and some of the patients
were found to actually be infected by enteroviruses in-
stead [18,19]. In this report, we consider only those pa-
tients whose admitting diagnosis was acute meningitis/
encephalitis, and whose infection was confirmed to be
due to E30 or JEV by laboratory procedures. Our study
focused on the clinical information of these patients, and
we found that specific clinical symptoms and laboratory
findings could give the clinicians/epidemiologists a more




This study was approved by the Institutional Review Board
of the National Institute of Hygiene and Epidemiology
(NIHE), Vietnam (No: 01 IRB, November 7, 2005, No: 33
IRB, December 15, 2011).
Specimen collection
Cerebrospinal fluid (CSF) specimens were collected only
from patients who were clinically diagnosed to have acute
meningitis/encephalitis at the time of admission and whoseclinical records were available. The patients were from the
National Hospital of Pediatrics (NHP) in Hanoi, Northern
Vietnam and from Bac Giang General Hospital (BGGH)
in Bac Giang, Northern Vietnam. The period of collection
at the NHP was from 2001–2002, when an E30 outbreak
occurred in Hanoi. The period of collection at BGGH was
from 1999 to 2008. NIHE collects clinical specimens from
BGGH annually because it is located in a JEV endemic
area [16].
Laboratory investigation
CSF specimens were sent to the NIHE for laboratory diag-
nosis. The E30 cases were identified by the neutralization
test (NT) using anti-E30 serum [20]. Several samples that
were unidentified by the NT were subjected to the virus
isolation and gene amplification method as described
below. The JEV cases were confirmed by IgM Capture
ELISA [16].
Virus isolation, RT-PCR, and sequencing
Eight unidentified samples were subjected to virus isola-
tion. Each CSF specimen was inoculated in human
rhabdomyosarcoma cells (RD cells). The cells were incu-
bated at 37°C with 5% CO2 until the cytopathic effect
(CPE) was observed under a microscope [21,22]. Then,
the infected culture fluids (ICFs) were collected and kept
at −80°C prior to use. The viral RNA was isolated from
the ICFs by the QIAamp Viral RNA Mini Kit (QIAGEN)
according to the manufacturer’s instructions [23]. To
amplify the complete VP1 gene of E30, RNA templates
were subjected to reverse transcription and polymerase
chain reaction (RT-PCR) using the forward primer 5′-
GCRTGCAATGAYTTCTCWGT-3′ and the reverse pri-
mer 5′-GCICCIGAYTGITGICCRAA-3′ [24]. The am-
plicons were sequenced using the ABI PRISM 3100-Avant
Genetic Analyzer [25].
Phylogenetic analysis
Phylogenetic analysis of selected strains of human E30
from different geographical origins was performed based
on the VP1 gene sequences (Figure 1). Alignment of
these sequences was performed by Clustal W version 2.0
[26], and a neighbor-joining tree [27] was generated
using MEGA 5.0 software [28]. The prototype strain
Farina of Echovirus 21 (GenBank accession number:
AY302547) was used as the out-group. The reliability of
the phylogenetic tree was determined by a bootstrap
resampling test with 1,000 replicates.
Clinical data and statistical analysis
The clinical data from E30-confirmed cases (E30 group)
and JEV-confirmed cases (JEV group) were included in the
statistical analysis. The statistical analysis was conducted
using R version 2.15 software [29]. The difference between
Figure 1 (See legend on next page.)
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Figure 1 Phylogenetic analysis of the selected E30 strains. A phylogenetic analysis of VP1 gene sequences from the selected human E30
strains from different geographical origins was conducted. The neighbor-joining tree was generated using MEGA 5.0 software, and the prototype
strain Farina of echovirus 21 was used as the outgroup. The eight Vietnamese isolates are highlighted in the red colored box. The sequences
reported here have been deposited in GenBank with the accession numbers of KC999616 to KC999623.
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tests and Fisher Exact tests. The distribution of values
between these groups was compared by the F test, and
the difference of values between them was assessed by
Student’s t-tests or Welch tests. A P value of less than
0.05 was accepted as significant.
Results
Laboratory confirmation of E30 and JEV infection
Eighty-eight patients from NHP were confirmed to have
E30 infection based on NT (80 patients) and virus isola-
tion (8 patients) (Figure 2). One hundred thirty-four pa-
tients at BGGH were confirmed to have JEV infection by
IgM Capture ELISA (Figure 2).
Virus isolation, sequence comparison, and
phylogenetic analysis
E30 was isolated from eight CSF specimens. The VP1
gene in these isolates was sequenced. The designated
strain name of each isolate and the corresponding
GenBank accession number (enclosed in parentheses
below) were as follows: 01VN80 (KC999616), 01VN89Figure 2 Flow-chart of the work and some of the results in this
study. CSF specimens were collected from patients who were
clinically diagnosed with acute meningitis/encephalitis at the time of
admission to the National Hospital of Pediatrics (NHP) during 2001–
2001 and Bac Giang General Hospital (BGGH) during 1999–2008. CSF
specimens were sent to NIHE for laboratory diagnosis. A total of 88
patients from NHP were confirmed to be infected with E30 based
on NT (80 patients) and virus isolation (8 patients) but only 43
patients had available clinical records. From BGGH, a total of 134
patients were confirmed to be infected with JEV based on the IgM
Capture ELISA but only 60 had clinical records.(KC999617), 01VN90 (KC999618), 01VN92 (KC999619),
01VN102 (KC999620), 01VN104 (KC999621), 02VN24
(KC999622), and 02VN28 (KC999623).
We constructed the NJ tree of these eight Vietnamese
strains together with the 88 E30 strains from GenBank
based on the VP1 gene sequence. Based on this tree, our
identified strains were relatively close to the Asian
strains that caused aseptic meningitis (Figure 1).
Epidemiological features
Most patients were under 15 years old in both the E30
and the JEV groups. The median age was 7 in the former
group and 6 in the latter group. In the E30 group, there
were 30 male patients (70%) and 13 female patients
(30%), with a male-to-female ratio of 2.3:1. In the JEV
group, there were 22 male patients (37%) and 38 female
patients (63%), with a male-to-female ratio of 1:1.7. The
percentage of JEV-vaccinated patients in the E30 group
was significantly higher than that in the JEV group (E30
vs. JEV: 56% vs. 12%, p < 0.001) (Table 1). Fatal (12%)
and sequelae (10%) cases were observed in the JEV
group only (Table 1). Both E30 and JEV cases occurred
more frequently during the summer season from May to
July (Figure 3).
Clinical features during admission
The clinical features during admission of the E30 and the
JEV patients are shown in Table 2. The vital sign parame-
ters (body temperature, pulse rate, and respiratory rate)
on admission day showed no significant difference be-
tween the two groups of patients. A longer hospitalization
period was observed in the JEV group than in the E30
group (E30 vs. JEV: 7 [range: 3–23] vs. 9 [1–37] days, p =
0.003). More patients in the E30 group complained of
headache (95% vs. 50%, p < 0.001), vomiting (98% vs. 33%,
p < 0.001), abdominal symptoms (19% vs. 5%, p = 0.048),
and neck or back pain (26% vs. 2%, p < 0.001). On the
other hand, more patients in the JEV group had a higher
maximum body temperature (38.0 [37.0-41.0] vs. 38.8
[37.0-40.0] °C, p = 0.010), altered consciousness (12% vs.
97%, p < 0.001), and seizures (5% vs. 73%, p < 0.001). The
periods of altered consciousness (1 [1-3] vs. 3 [1-17] days,
p = 0.002), seizures (1 [1] vs. 2 [1-7] days, p < 0.001),
Babinski reflex (1 [1-3] vs. 2 [1-7] days, p = 0.001), and
focal neurological signs (1 [1] vs. 2.5 [1-13] days, p =
0.037) lasted longer in the JEV group. Both groups had a
similar percentage of patients with signs of meningeal irri-
tations, whereas the duration period was longer in the JEV
Table 1 Basic patient information and outcome
Median age [range] or number of
patients (%)
E30 patients JEV patients p-value
n = 43 n = 60
Age 7 [0.4-14] 6 [0.8-21] 0.916
Sex Male 30 (70) 22 (37)
Female 13 (30) 38 (63)
Family/neighbor
history1
1 (2) 1 (2) 0.628
JEV vaccination 24 (56) 7 (12) <0.001*
Death 0 (0) 7 (12) 0.040*
Sequelae 0 (0) 6 (10) 0.039*
1family or neighbor showed similar symptoms as the patient at that time,
*significant difference (p < 0.05).
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in the JEV group experienced Babinski reflex (42% vs.
62%, p = 0.047), and with a longer duration (1 [1-3] vs. 2
[1-7] days, p = 0.001). Hemiplegia was observed only in
the JEV group (25%, p < 0.001).
We also focused on the symptoms observed simultan-
eously. The combined symptoms of headache and vomiting
and the triad of symptoms of fever, headache, and vomiting
were observed in more patients in the E30 group (19% vs.
0%, p < 0.001 and 74% vs. 27%, p < 0.001, respectively). On
the other hand, occurrence of the combined symptoms ofFigure 3 Monthly distribution and frequency of E30 and JEV
cases. There were 43 confirmed E30 cases from NHP during
2001–2002 and 60 JEV confirmed cases from BGGH during
1999–2008. The E30 cases and the JEV cases were totaled
separately according to the month and regardless of the year of
occurrence. The total number of cases per month from January to
December was plotted in the graph. The peak for both cases was
from May to July.fever and headache was observed only in the JEV group
(18%, p = 0.002).
Laboratory findings
The results of the CSF and blood examination are shown
in Table 3. CSF leucocytes were significantly increased in
the E30 group (80 [1–750] vs. 18 [5–350] cells/μL, p =
0.003). An increased number of both CSF neutrophils
and CSF lymphocytes was observed in the E30 group
(neutrophils: 26 [2–381] vs. 10 [3–140] cells/μL, p =
0.033, lymphocytes: 56 [3–676] vs. 12 [4–210] cells/μL,
p = 0.043). The CSF sugar levels were significantly de-
creased in the JEV group (58.7 [27–90] vs. 46.9 [25–74]
mg/dL, p < 0.001). Other indicators of CSF and blood
components showed no significant difference between
the E30 and the JEV groups.
Treatment features
The laboratory diagnosis required at least one week to
complete, thus medication was given even before the re-
sults of the diagnosis became available. The medication
histories of the E30 and the JEV groups are shown in
Table 4. A history of the use of steroids showed no sig-
nificant difference between the two groups (E30 vs. JEV:
98% vs. 97%). The duration of steroids use also showed
no difference in both groups (3 [2-4] vs. 3 [2-15] days).
More patients were prescribed mannitol (47% vs. 95%, p <
0.001) and antibiotics (35% vs. 95%, p < 0.001) in the JEV
group. The duration of mannitol use was longer in the
JEV group (1 [1-3] vs. 3 [1-7] days, p < 0.001). A history of
the use of diazepam showed no significant difference be-
tween the two groups. The duration of diazepam use was
longer in the E30 group (6 [2-14] vs. 2 [1-11] days, p <
0.001). More patients in the JEV group were prescribed
barbiturates (33% vs. 63%, p = 0.002), chlorpromazine
(5% vs. 23%, p = 0.012), fentanyl (0% vs. 33%, p < 0.001),
and sodium valproate (0% vs. 33%, p < 0.001).
Discussion
E30 and JEV are the causative agents of acute meningi-
tis/encephalitis in Asian countries. In the present report,
Vietnamese patients with an admitting diagnosis of acute
meningitis/encephalitis were confirmed to have either
E30 or JEV infection by a laboratory diagnosis. The E30
CSF samples analyzed in the present study were col-
lected during the outbreak in 2001–2002. Eight E30
strains were isolated from this outbreak, and the phylo-
genetic analysis showed that these are relatively close to
the strains isolated during E30 outbreaks from other
Asian countries (Figure 1).
The E30 acute meningitis/encephalitis outbreak in
2001–2002 gained our interest because nearly all of the pa-
tients were clinically diagnosed to have Japanese encepha-
litis at the beginning of their hospitalization. The reason
Table 2 Clinical features during admission
Clinical feature(s) Median [range] or, number of patients with the feature (%) p-value
E30 patients JEV patients
n = 43 n = 60
Body temperature (°C)1 38.0 [36.2-41.0] 38.5 [36.5-40.0] 0.096
Pulse rate (beats per min.)1 100 [80–120] {34}2 100 [70–145] {58}2 0.092
Respiratory rate (breaths per min.)1 26 [20–45] {13}2 26 [20–50] {31}2 0.691
Length of stay in the hospital (day) 7 [3-23] 9 [1–37] 0.003*
Highest body temperature (°C) 38.0 [37.0-41.0] 38.8 [37.0-40.0] 0.010*
Period of fever3 (day) 1 [1-14] 2 [1-7] 0.259
Headache 41 (95) 30 (50) < 0.001*
Period of headache (day) 2 [1-7] {41} 2.5 [1-12] {30} 0.006*
Vomiting 42 (98) 20 (33) < 0.001*
Period of vomiting (day) 1 [1-5] {42} 1 [1,2] {20} 0.526
Altered consciousness 5 (12) 58 (97) < 0.001*
Period of altered consciousness (day) 1 [1-3] {5} 3 [1-17] {58} 0.002*
Seizure 2 (5) 44 (73) < 0.001*
Period of seizure (day) 1 [1] {2} 2 [1-7] {44} < 0.001*
Sign of meningeal irritation 30 (70) 41 (68) 0.877
Period of meningeal irritation (day) 1 [1-6] {30} 3 [1-14] {41} 0.002*
Babinski reflex 18 (42) 37 (62) 0.047*
Period of Babinski reflex (day) 1 [1-3] {18} 2 [1-7] {37} 0.001*
Focal neurological sign 2 (5) 10 (17) 0.070
Period of focal neurological sign (day) 1 [1] {2} 2.5 [1-13] {10} 0.037*
Dyspnea 2 (5) 10 (17) 0.070
Hemiplegia 0 (0) 15 (25) < 0.001*
Fatigue 14 (33) 22 (37) 0.666
Abdominal symptom 8 (19) 3 (5) 0.048*
Neck or back pain 11 (26) 1 (2) < 0.001*
Joint pain 1 (2) 0 (0) 0.235
Skin rash 0 (0) 1 (2) 0.395
Fever3 + Headache 0 (0) 11 (18) 0.002*
Headache + Vomiting 8 (19) 0 (0) < 0.001*
Vomiting + Fever3 4 (9) 2 (3) 0.232
Fever3 + Headache + Vomiting 32 (74) 16 (27) < 0.001*
1taken on the day of admission, 2number inside curly brackets refer to the number of patients with the record, 3fever defined as body temperature of over 38°C,
*significant difference (p < 0.05).
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lines for differentiating E30 from JEV infections based on
the clinical symptoms and case histories. Our study is the
first report to show that certain clinical features could dif-
ferentiate E30 from JEV cases.
We tried to compare the symptoms and clinical features
between the two groups before admission, according to
the information in the clinical record (unpublished data).
However, there was no sufficient difference noted between
the E30 and the JEV cases compared to those during ad-
mission (Table 2). Then, we focused our attention on thedata during the admission period. Here, we noted that the
most common symptoms were fever, headache, and
vomiting for both the E30 and the JEV groups (Table 2).
More patients in the E30 group had the combined symp-
toms of headache and vomiting and the triad of symptoms
(fever, headache, and vomiting) (Table 2). Thus, it is con-
cluded that these combined symptoms could indicate a
high probability of E30 infection. Findings on magnetic
resonance imaging (MRI) of patients in the E30 cases re-
vealed no significant abnormalities in the brain [7]. It
seems that the mild neurological symptoms observed in
Table 3 CSF and blood examination
Median value (range), [number of patients]
p-valueE30 patients JEV patients
n = 43 n = 60
CSF protein (mg/dL) 36.3 (14–144) [39] 44.5 (6–100) [47] 0.093
CSF sugar (mg/dL) 58.7 (27–90) [38] 46.9 (25–74) [47] < 0.001*
CSF leucocyte (cells/μL) 80 (1–750) [41] 18 (5–350) [45] 0.003*
CSF neutrophil (cells/μL) 26 (2–381) [23] 10 (3–140) [35] 0.033*
CSF lymphocyte (cells/μL) 56 (3–676) [23] 12 (4–210) [35] 0.043*
Blood leucocyte (10E3 cells/μL) 10.4 (5.8-34) [19] 12.0 (3.0-30) [59] 0.711
Blood neutrophil (10E3 cells/μL) 8.2 (3.9-25) [18] 8.0 (1.1-26) [57] 0.368
Blood lymphocyte (10E3 cells/μL) 2.1 (1.3-9.6) [18] 3.2 (1.3-12) [57] 0.189
*significant difference (p < 0.05).
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from increased intracranial pressure. Therefore, vomiting,
which is one of the important signs of increased intracra-
nial pressure, was often observed in the E30 group com-
pared to the JEV group in this study.
More patients had altered consciousness (97%), seizure
(73%), and hemiplegia (25%) in the JEV group (Table 2).
These symptoms are strong signs of neural pathoge-
nicity. It was reported that the JEV patients showed ab-
normalities in thalamus, basal ganglia, and cerebral
cortex based on the results of computed tomography
(CT) and MRI [30-32]. However, it is difficult to conduct
these expensive examinations in a resource limiting set-
ting in the rural areas of Asian countries. Neuropatho-
logical findings in fatal JEV cases showed that the virus





Period of treatment 3 [2-4]
Mannitol 20 (47)
Period of treatment 1 [1-3]
Antibiotics 15 (35)
Period of treatment 8 [1-15]
Diazepam 23 (53)
Period of treatment 6 [2-14]
Barbiturate 14 (33)
Period of treatment 3.5 [1-14]
Chlorpromazine 2 (5)
Fentanyl 0 (0)
Sodium Valproate 0 (0)
*significant difference (p < 0.05).[33]. JEV infects neurons and causes direct damage
[10,33] that consequently leads to many severe neuro-
logical symptoms. Thus, in areas where E30 and JEV out-
breaks are overlapping, severe neurological symptoms
could provide strong evidence of JEV infection.
The most critical laboratory finding in this report was the
CSF leukocytosis in the E30 group (Table 3). An increase in
CSF neutrophils was observed, and this was also reported in
another study [34]. An increase in CSF lymphocytes was
observed in the present study. Therefore, these results seem
to suggest that CSF leukocytosis relates to the E30 infection.
Based on the medication history, more patients were pre-
scribed barbiturates, chlorpromazine, fentanyl, and sodium
valproate in the JEV group (Table 4). This seems to correlate
with the longer period of neurological symptoms such





57 (95) < 0.001*
3 [1-7] < 0.001*
57 (95) < 0.001*
8 [1-17] 0.688
32 (53) 0.988




20 (33) < 0.001*
20 (33) < 0.001*
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egies have been established in each hospital, however
some minor differences in these strategies exist between
hospitals.
Patients in the E30 group had a higher male-to-female
ratio of 2.3:1. A higher ratio was also shown in previous
reports [34,35]. Boys usually prefer to play outside of their
house compared with girls. This behavior could result
in a more frequent exposure of boys to the pathogen.
Conclusion
Clinical information demonstrated that the combination
of headache and vomiting and the triad of symptoms of
fever, headache, and vomiting could indicate a high
probability of E30 infection. A laboratory parameter of
CSF leukocytosis also suggests E30 infection. On the
other hand, strong neurological symptoms, such as al-
tered consciousness, seizure, and hemiplegia, could indi-
cate a high probability of JEV infection. These findings
will help improve the clinical diagnosis of patients with
E30 or JEV meningitis/encephalitis. Then, proper mea-
sures can be adopted for the clinical management of the
patients at the early phase of admission before labora-
tory diagnosis becomes available.
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